Schrödinger Reports Q3 2026 Financial Results and Strategic Updates

Schrödinger reported Q3 2026 revenue of $64.49 million, above analyst estimates, with hosted software revenue up 49% and an adjusted loss of $0.50 per share. It amended its Novartis collaboration, replacing existing programs with two new ones and raising potential milestone payments to $1.424 billion. Bristol Myers Squibb adopted Schrödinger’s Bunsen platform, now in early access ahead of a planned year-end commercial release; the company also launched Tectora with two licensed programs. Schrödinger plans to present updated Phase 1 data for SGR-1505 in December 2026.